

Greenhouse Gas Verification Statement

The inventory of Greenhouse Gas emissions in the period
01/01/2022 – 31/12/2022 for

TEVA PHARMACEUTICAL INDUSTRIES LTD

124 Dvora Ha-nevi'a Tel Aviv (Israel)

has been verified in accordance with ISO 14064-3:2019 as
meeting the requirements of

GHG PROTOCOL

*For the following activities: Pharmaceutical Industries, offices, R&D, centers and logistics
centers*

Approved by



M^a Lourdes Martín Mangas

Technical Director of Sustainability and Climate Change

Date: 20th April 2023

SGS Tecnos S.A.U.

C/Trespaderne 29, Edificio Barajas I, 2^a Planta, 28042 – Madrid (España)

www.sgs.es

*This Statement is not valid without the full verification scope, objectives, criteria and conclusion available on pages 2
to 5 of this Statement*



Greenhouse Gases Verification Statement

TEVA PHARMACEUTICAL INDUSTRIES LTD provided the GHG assertion based on the requirements of GHG Protocol. The GHG emissions for the year 2022 have been verified by SGS to a limited level of assurance, consistent with the agreed verification scope, objectives and criteria.

The emissions are broken down into the following categories:

t CO2e	Year 2022
Scope 1- Direct GHG emissions	254,632
Scope 2- Electricity indirect GHG emissions	244,009
TOTAL	498,641

SGS has planned and performed the current work to obtain the information, explanations and evidence considered necessary to provide a limited level of assurance that the CO2 equivalent emissions for the year 2022 are fairly stated. Our verification of the GHG Assertion of TEVA PHARMACEUTICAL INDUSTRIES LTD includes the evaluation of the GHG information system, its control, and its notification protocol. This verification has included the collection of evidence supporting the reported data, and the verification of the correct application of TEVA PHARMACEUTICAL INDUSTRIES LTD procedures.

Opinion

Based on the process and procedures conducted, SGS concludes that there is no evidence that the presented CO2 equivalent assertion:

- Is not materially correct and is not a fair representation of GHG data and information, and
- Has not been prepared in accordance with the requirements of GHG Protocol, in relation to its quantification, control and notification.

This statement shall be interpreted with the CO2 equivalent assertion "Teva GHG Report 2022" as a whole.

Note: This Statement is issued, on behalf of Client, by SGS Tecnos S.A.U. ("SGS") under its General Conditions included in http://www.sgs.com/terms_and_conditions.htm. A full copy of this statement and the supporting GHG Assertion may be consulted at TEVA PHARMACEUTICAL INDUSTRIES LTD. This Statement does not relieve Client from compliance with any bylaws, federal, national or regional acts and regulations or with any guidelines issued pursuant to such regulations. Stipulations to the contrary are not binding on SGS and SGS shall have no responsibility vis-à-vis parties other than its Client.



Schedule Accompanying Greenhouse Gas Verification Statement Number

SGS has been contracted by TEVA PHARMACEUTICAL INDUSTRIES LTD, for the verification of direct and indirect carbon dioxide (CO2) equivalent emissions as provided by TEVA PHARMACEUTICAL INDUSTRIES LTD in their GHG assertion "Teva GHG Report 2022", covering the period 01/01/2022 – 31/12/2022 and considering 2019 as the base year.

Responsibilities

The management of TEVA PHARMACEUTICAL INDUSTRIES LTD is responsible for the organization's GHG information system, the development and maintenance of records and reporting procedures in accordance with that system, including the calculation and determination of GHG emissions information and the reported GHG emissions.

It is SGS' responsibility to express an independent GHG verification opinion on the GHG emissions as provided in their GHG Assertion for the period 01/01/2022 – 31/12/2022,

SGS conducted a third party verification following the requirements of GHG Protocol and ISO 14064-3:2019 of the provided CO2 equivalent assertion "Teva GHG Report 2022", for the period 01/01/2022 – 31/12/2022.

Level of Assurance

The level of assurance agreed for the assignment is a limited level of assurance.

Scope

TEVA PHARMACEUTICAL INDUSTRIES LTD has commissioned an independent verification by SGS of reported CO2 equivalent emissions arising from their activities, to establish conformance with the requirements of GHG Protocol in their facilities located in 124 Dvora Ha-nevi'a Tel Aviv (Israel).



The reporting boundaries have been:

- Scope 1: Direct GHG emissions:
 - Stationary combustion.
 - Mobile combustion (transport).
 - Process emissions.
 - Fugitive emissions.
 - Refrigerants.
- Scope 2: Electricity indirect GHG emissions:
 - Purchased electricity, including Non-RA sites Electricity.
 - Heat production.
 - Steam production.

The exclusions have been:

None

The organizational boundaries were established following the **operational** control approach.

This engagement covers verification of emissions and removals of greenhouse gases included within the organization's boundaries and meets the requirements of ISO 14064-3:2019.

- **Title and description of activities:** Verification of the GHG assertion for TEVA PHARMACEUTICAL INDUSTRIES LTD year 2022.
- **Location of the activities:** 124 Dvora Ha-nevi'a Tel Aviv (Israel).
- **Activities of the organization:** Pharmaceutical Industries, offices, R&D, centers and logistics centers
- Types of **GHGs** included: CO₂, CH₄, N₂O, HFCs, SF₆, NF₃ and PFC.
- The **verification** period is: 01/01/2022 – 31/12/2022

Objetives

The purposes of this verification exercise are, by review of objective evidence, to independently review:

- Whether the CO₂ equivalent emissions are as declared by the organization's CO₂ equivalent assertion.
- That the data reported are accurate, complete, consistent, transparent and free of material error or omission.
- Whether the inventory system complies with the criteria and scope established in the GHG Protocol.



Criteria

Criteria against which the verification assessment is undertaken are the requirements of ISO 14064-3:2019.

Materiality

The materiality required of the verification was considered by SGS to be below 10%.

Note: This Statement is issued, on behalf of Client, by SGS Tecnos S.A.U. ("SGS") under its General Conditions included in http://www.sgs.com/terms_and_conditions.htm. A full copy of this statement and the supporting GHG Assertion may be consulted at TEVA PHARMACEUTICAL INDUSTRIES LTD. This Statement does not relieve Client from compliance with any bylaws, federal, national or regional acts and regulations or with any guidelines issued pursuant to such regulations. Stipulations to the contrary are not binding on SGS and SGS shall have no responsibility vis-à-vis parties other than its Client.

